Metformin + Dapagliflozin Tablets Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: (dapagliflozin/metformin): 5 mg/500 mg, 5 mg/1000 mg, 10 mg/500 mg, 10 mg/1000 mg
Reference Brands: Xigduo XR®(US and EU)
Category:
Diabetes
Dapagliflozin/metformin (Xigduo XR) combines two mechanisms: dapagliflozin, an SGLT2 inhibitor, reduces blood glucose by increasing urinary glucose excretion, while metformin decreases hepatic glucose production and improves insulin sensitivity. Benefits include improved glycemic control, weight loss, and reduced cardiovascular risk in type 2 diabetes patients.
Metformin + Dapagliflozin Tablets is available in Tablets
and strengths such as (dapagliflozin/metformin): 5 mg/500 mg, 5 mg/1000 mg, 10 mg/500 mg, 10 mg/1000 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Metformin + Dapagliflozin Tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Metformin + Dapagliflozin Tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
In the US, dapagliflozin/metformin (Xigduo XR) was approved by the FDA in February 2014 for type 2 diabetes as an adjunct to diet and exercise, with a warning to stop temporarily before surgery to reduce ketoacidosis risk. In the EU, Xigduo received marketing authorization in January 2014, and Ebymect in November 2015, for glycemic control in adults when metformin alone is inadequate. The EMA expanded metformin use in 2016 to patients with moderate kidney impairment (GFR 30–59 ml/min), with dose adjustments and monitoring for lactic acidosis. For sourcing, check Pharmatradz.com for supplier details and availability
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing